XXXX PET/CT to predict response to neoadjuvant chemotherapy and prognosis in @entity0 .

@entity1 @entity20948 @entity0 @entity419 @entity66 @entity5
UNASSIGNED: The aim of this prospective study was to assess the predictive value of @entity419 PET/CT imaging for pathologic response to neoadjuvant chemotherapy (NACT) and outcome in @entity0 ( @entity0 ) @entity1 . METHODS: Twenty-three consecutive @entity1 (51 years  12.7) with newly diagnosed @entity0 , assessed by PET/CT scan at baseline ( @entity20948 ), after the third course of NACT (PET2) and before surgery (PET3), were included. @entity1 were divided into 2 groups according to the pathologic response assessed by the Sataloff classification: pCR for complete responders (TA and NA or NB) and non-pCR for non-complete responders (not stage A for @entity5 and/or not NA or NB for lymph nodes). In addition to SUVmax measurements, a global breast Metabolic Tumor Volume (MTV) was delineated using a semi-automatic segmentation method. Changes of SUVmax and MTV between @entity20948 and PET2 (  SUV1-2;   MTV1-2) and @entity20948 and PET3 (  SUV1-3;   MTV1-3) were measured. RESULTS: Mean SUVmax on @entity20948 , PET2 and PET3 were not statistically different between the 2 pathologic response groups. Using ROC analysis, a 72% cutoff of   SUV1-3 provided the best performance to predict @entity66 with sensitivity, specificity and accuracy of 61%, 80%, and 65%, respectively. On univariate analysis, the 72% cutoff of   SUV1-3 was the best predictor of Distant Metastasis-Free Survival (P = 0.05). On multivariate analysis, the 72% cutoff   SUV1-3 was an independent predictor of DMFS (P = 0.01). CONCLUSION: Our results emphasize the good predictive value of   SUVmax between baseline and before surgery to assess pathologic response and survival in @entity0 @entity1 undergoing NACT.
